Applications of Immunogenomics to Cancer

Cell

Volumn 168, Issue 4, 2017, Pages 600-612

  Liu, X Shirley ^a   Mardis, Elaine R ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; B LYMPHOCYTE RECEPTOR; PEPTIDE; T LYMPHOCYTE RECEPTOR; CANCER VACCINE; HLA ANTIGEN; TUMOR ANTIGEN;

CANCER GENETICS; CELLULAR IMMUNITY; GENOME; GENOMICS; HLA SYSTEM; IMMUNE SYSTEM; IMMUNOGENETICS; IMMUNOGENOMICS; INFORMATION; MALIGNANT NEOPLASM; PREDICTION; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; GENETICS; HUMAN; HUMAN GENOME; IMMUNOLOGY; MUTATION; NEOPLASM; SEQUENCE ANALYSIS;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; GENOME, HUMAN; HLA ANTIGENS; HUMANS; IMMUNOGENETICS; LYMPHOCYTES, TUMOR-INFILTRATING; MUTATION; NEOPLASMS; SEQUENCE ANALYSIS, PROTEIN;

EID: 85012159497     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.01.014     Document Type: Review

References (133)

1. Alamyar, E., Duroux, P., Lefranc, M.-P., Giudicelli, V., IMGT(®) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. Methods Mol. Biol. 882 (2012), 569–604.
2. Angelova, M., Charoentong, P., Hackl, H., Fischer, M.L., Snajder, R., Krogsdam, A.M., Waldner, M.J., Bindea, G., Mlecnik, B., Galon, J., Trajanoski, Z., Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol., 16, 2015, 64.
3. Aouinti, S., Malouche, D., Giudicelli, V., Kossida, S., Lefranc, M.-P., IMGT/HighV-QUEST Statistical Significance of IMGT Clonotype (AA) Diversity per Gene for Standardized Comparisons of Next Generation Sequencing Immunoprofiles of Immunoglobulins and T Cell Receptors. PLoS ONE, 10, 2015, e0142353.
4. Babbitt, B.P., Allen, P.M., Matsueda, G., Haber, E., Unanue, E.R., Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 317 (1985), 359–361.
5. Bagaev, D.V., Zvyagin, I.V., Putintseva, E.V., Izraelson, M., Britanova, O.V., Chudakov, D.M., Shugay, M., VDJviz: a versatile browser for immunogenomics data. BMC Genomics, 17, 2016, 453.
6. Bainbridge, M.N., Wang, M., Burgess, D.L., Kovar, C., Rodesch, M.J., D'Ascenzo, M., Kitzman, J., Wu, Y.-Q., Newsham, I., Richmond, T.A., et al. Whole exome capture in solution with 3 Gbp of data. Genome Biol., 11, 2010, R62.
7. Bassani-Sternberg, M., Bräunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun., 7, 2016, 13404.
8. Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A.C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39 (2013), 782–795.
9. Bjorkman, P.J., Saper, M.A., Samraoui, B., Bennett, W.S., Strominger, J.L., Wiley, D.C., Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329 (1987), 506–512.
10. Bolotin, D.A., Poslavsky, S., Mitrophanov, I., Shugay, M., Mamedov, I.Z., Putintseva, E.V., Chudakov, D.M., MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12 (2015), 380–381.
11. Calis, J.J.A., Rosenberg, B.R., Characterizing immune repertoires by high throughput sequencing: strategies and applications. Trends Immunol. 35 (2014), 581–590.
12. Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A.A., Ly, A., Lie, W.-R., Hildebrand, W.H., Mardis, E.R., Linette, G.P., Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 (2015), 803–808.
13. Carter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P.W., Onofrio, R.C., Winckler, W., Weir, B.A., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30 (2012), 413–421.
14. Cerottini, J.C., Engers, H.D., Macdonald, H.R., Brunner, T., Generation of cytotoxic T lymphocytes in vitro. I. Response of normal and immune mouse spleen cells in mixed leukocyte cultures. J. Exp. Med. 140 (1974), 703–717.
15. Cole, G.A., Interferon-γ ELISPOT Assay for the Quantitative Measurement of Antigen-Specific Murine CD8 T-Cells. Handbook of ELISPOT, 2005, Springer, 191–204.
16. Cole, C., Volden, R., Dharmadhikari, S., Scelfo-Dalbey, C., Vollmers, C., Highly Accurate Sequencing of Full-Length Immune Repertoire Amplicons Using Tn5-Enabled and Molecular Identifier-Guided Amplicon Assembly. J. Immunol. 196 (2016), 2902–2907.
17. Cornish, A., Guda, C., A Comparison of Variant Calling Pipelines Using Genome in a Bottle as a Reference. BioMed Res. Int., 2015, 2015, 456479.
18. De Plaen, E., Lurquin, C., Van Pel, A., Mariamé, B., Szikora, J.P., Wölfel, T., Sibille, C., Chomez, P., Boon, T., Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc. Natl. Acad. Sci. USA 85 (1988), 2274–2278.
19. DiLillo, D.J., Yanaba, K., Tedder, T.F., B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 184 (2010), 4006–4016.
20. Duan, F., Duitama, J., Al Seesi, S., Ayres, C.M., Corcelli, S.A., Pawashe, A.P., Blanchard, T., McMahon, D., Sidney, J., Sette, A., et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J. Exp. Med. 211 (2014), 2231–2248.
21. Dubey, P., Hendrickson, R.C., Meredith, S.C., Siegel, C.T., Shabanowitz, J., Skipper, J.C., Engelhard, V.H., Hunt, D.F., Schreiber, H., The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J. Exp. Med. 185 (1997), 695–705.
22. Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Yang, J.C., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Sherry, R., Restifo, N.P., Hubicki, A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002), 850–854.
23. Emerson, R.O., Sherwood, A.M., Rieder, M.J., Guenthoer, J., Williamson, D.W., Carlson, C.S., Drescher, C.W., Tewari, M., Bielas, J.H., Robins, H.S., High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J. Pathol. 231 (2013), 433–440.
24. Foley, E.J., Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13 (1953), 835–837.
25. Freeman, J.D., Warren, R.L., Webb, J.R., Nelson, B.H., Holt, R.A., Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res. 19 (2009), 1817–1824.
26. Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J.-M., Buqué, A., Senovilla, L., Baracco, E.E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. Classification of current anticancer immunotherapies. Oncotarget 5 (2014), 12472–12508.
27. Gao, J., Shi, L.Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S.E., et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167 (2016), 397–404.e9.
28. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al., KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 2018–2028.
29. Ghoneim, D.H., Myers, J.R., Tuttle, E., Paciorkowski, A.R., Comparison of insertion/deletion calling algorithms on human next-generation sequencing data. BMC Res. Notes, 7, 2014, 864.
30. Gillis, S., Smith, K.A., Long term culture of tumour-specific cytotoxic T cells. Nature 268 (1977), 154–156.
31. Giudicelli, V., Chaume, D., Bodmer, J., Müller, W., Busin, C., Marsh, S., Bontrop, R., Marc, L., Malik, A., Lefranc, M.P., IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 25 (1997), 206–211.
32. Gnirke, A., Melnikov, A., Maguire, J., Rogov, P., LeProust, E.M., Brockman, W., Fennell, T., Giannoukos, G., Fisher, S., Russ, C., et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27 (2009), 182–189.
33. Greiff, V., Miho, E., Menzel, U., Reddy, S.T., Bioinformatic and Statistical Analysis of Adaptive Immune Repertoires. Trends Immunol. 36 (2015), 738–749.
34. Greiff, V., Bhat, P., Cook, S.C., Menzel, U., Kang, W., Reddy, S.T., A bioinformatic framework for immune repertoire diversity profiling enables detection of immunological status. Genome Med., 7, 2015, 49.
35. Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C.D., Krebber, W.-J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
36. Gubin, M.M., Artyomov, M.N., Mardis, E.R., Schreiber, R.D., Tumor neoantigens: building a framework for personalized cancer immunotherapy. J. Clin. Invest. 125 (2015), 3413–3421.
37. Herbst, R.S., Soria, J.-C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
38. Hirayama, M., Nishimura, Y., The present status and future prospects of peptide-based cancer vaccines. Int. Immunol. 28 (2016), 319–328.
39. Hodges, E., Rooks, M., Xuan, Z., Bhattacharjee, A., Benjamin Gordon, D., Brizuela, L., Richard McCombie, W., Hannon, G.J., Hybrid selection of discrete genomic intervals on custom-designed microarrays for massively parallel sequencing. Nat. Protoc. 4 (2009), 960–974.
40. Hou, X.-L., Wang, L., Ding, Y.-L., Xie, Q., Diao, H.-Y., Current status and recent advances of next generation sequencing techniques in immunological repertoire. Genes Immun. 17 (2016), 153–164.
41. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165 (2016), 35–44.
42. Imai, C., Mihara, K., Andreansky, M., Nicholson, I.C., Pui, C.-H., Geiger, T.L., Campana, D., Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18 (2004), 676–684.
43. Jiang, Y., Wang, Y., Brudno, M., PRISM: pair-read informed split-read mapping for base-pair level detection of insertion, deletion and structural variants. Bioinformatics 28 (2012), 2576–2583.
44. Jiang, Y., Turinsky, A.L., Brudno, M., The missing indels: an estimate of indel variation in a human genome and analysis of factors that impede detection. Nucleic Acids Res. 43 (2015), 7217–7228.
45. Johnson, P.L.F., Goronzy, J.J., Antia, R., A population biological approach to understanding the maintenance and loss of the T-cell repertoire during aging. Immunology 142 (2014), 167–175.
46. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., June, C.H., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 2011, 95ra73.
47. Klein, A.M., Mazutis, L., Akartuna, I., Tallapragada, N., Veres, A., Li, V., Peshkin, L., Weitz, D.A., Kirschner, M.W., Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 161 (2015), 1187–1201.
48. Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M., Sadelain, M., Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31 (2013), 71–75.
49. Knuth, A., Danowski, B., Oettgen, H.F., Old, L.J., T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc. Natl. Acad. Sci. USA 81 (1984), 3511–3515.
50. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.-A.N., Lanier, B.J., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 (2010), 4099–4102.
51. Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J.C., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520 (2015), 692–696.
52. Kroeger, D.R., Milne, K., Nelson, B.H., Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer. Clin. Cancer Res. 22 (2016), 3005–3015.
53. Krøigård, A.B., Thomassen, M., Lænkholm, A.-V., Kruse, T.A., Larsen, M.J., Evaluation of Nine Somatic Variant Callers for Detection of Somatic Mutations in Exome and Targeted Deep Sequencing Data. PLoS ONE, 11, 2016, e0151664.
54. Kumar, S., Razzaq, S.K., Vo, A.D., Gautam, M., Li, H., Identifying fusion transcripts using next generation sequencing. Wiley Interdiscip. Rev. RNA 7 (2016), 811–823.
55. Lao, X.-M., Liang, Y.-J., Su, Y.-X., Zhang, S.-E., Zhou, X.I., Liao, G.-Q., Distribution and significance of interstitial fibrosis and stroma-infiltrating B cells in tongue squamous cell carcinoma. Oncol. Lett. 11 (2016), 2027–2034.
56. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
57. Ley, T.J., Mardis, E.R., Ding, L., Fulton, B., McLellan, M.D., Chen, K., Dooling, D., Dunford-Shore, B.H., McGrath, S., Hickenbotham, M., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456 (2008), 66–72.
58. Li, B., Li, J.Z., A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. Genome Biol., 15, 2014, 473.
59. Li, Y., Chien, J., Smith, D.I., Ma, J., FusionHunter: identifying fusion transcripts in cancer using paired-end RNA-seq. Bioinformatics 27 (2011), 1708–1710.
60. Li, B., Li, T., Pignon, J.-C., Wang, B., Wang, J., Shukla, S.A., Dou, R., Chen, Q., Hodi, F.S., Choueiri, T.K., et al. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat. Genet. 48 (2016), 725–732.
61. Li, B., Severson, E., Pignon, J.-C., Zhao, H., Li, T., Novak, J., Jiang, P., Shen, H., Aster, J.C., Rodig, S., et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol., 17, 2016, 174.
62. Lundegaard, C., Lund, O., Nielsen, M., Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24 (2008), 1397–1398.
63. Lundegaard, C., Lamberth, K., Harndahl, M., Buus, S., Lund, O., Nielsen, M., NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36 (2008), W509–W512.
64. McNeel, D.G., TCR diversity - a universal cancer immunotherapy biomarker?. J. Immunother. Cancer, 4, 2016, 69.
65. Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A.R., Kamitaki, N., Martersteck, E.M., et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell 161 (2015), 1202–1214.
66. Mardis, E.R., DNA sequencing technologies: 2006-2016. Nat. Protoc. 12 (2017), 213–218.
67. McKinney, D.M., Southwood, S., Hinz, D., Oseroff, C., Arlehamn, C.S.L., Schulten, V., Taplitz, R., Broide, D., Hanekom, W.A., Scriba, T.J., et al. A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics 65 (2013), 357–370.
68. Milone, M.C., Fish, J.D., Carpenito, C., Carroll, R.G., Binder, G.K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17 (2009), 1453–1464.
69. Monach, P.A., Meredith, S.C., Siegel, C.T., Schreiber, H., A unique tumor antigen produced by a single amino acid substitution. Immunity 2 (1995), 45–59.
70. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006), 126–129.
71. Mose, L.E., Wilkerson, M.D., Hayes, D.N., Perou, C.M., Parker, J.S., ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics 30 (2014), 2813–2815.
72. Mose, L.E., Selitsky, S.R., Bixby, L.M., Marron, D.L., Iglesia, M.D., Serody, J.S., Perou, C.M., Vincent, B.G., Parker, J.S., Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V'DJer. Bioinformatics 32 (2016), 3729–3734.
73. Muraro, P.A., Robins, H., Malhotra, S., Howell, M., Phippard, D., Desmarais, C., de Paula Alves Sousa, A., Griffith, L.M., Lim, N., Nash, R.A., Turka, L.A., T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J. Clin. Invest. 124 (2014), 1168–1172.
74. Narzisi, G., O'Rawe, J.A., Iossifov, I., Fang, H., Lee, Y.-H., Wang, Z., Wu, Y., Lyon, G.J., Wigler, M., Schatz, M.C., Accurate de novo and transmitted indel detection in exome-capture data using microassembly. Nat. Methods 11 (2014), 1033–1036.
75. Nelson, B.H., CD20+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol. 185 (2010), 4977–4982.
76. Newell, E.W., Sigal, N., Bendall, S.C., Nolan, G.P., Davis, M.M., Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity 36 (2012), 142–152.
77. Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., Alizadeh, A.A., Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12 (2015), 453–457.
78. Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S.L., Lamberth, K., Buus, S., Brunak, S., Lund, O., Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12 (2003), 1007–1017.
79. Old, L.J., Boyse, E.A., IMMUNOLOGY OF EXPERIMENTAL TUMORS. Annu. Rev. Med. 15 (1964), 167–186.
80. Overwijk, W.W., Wang, E., Marincola, F.M., Rammensee, H.-G., Restifo, N.P., Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. J. Immunother. Cancer, 1, 2013, 11.
81. Pasternack, M.S., Review of Fundamental Immunology Edited by William E. Paul. 3rd edition, 1994, Raven Press, New York 1993. 1,490 pp., illustrated. 95. Clin. Infect. Dis. 19, 996–997.
82. Perricone, M.A., Smith, K.A., Claussen, K.A., Plog, M.S., Hempel, D.M., Roberts, B.L., St George, J.A., Kaplan, J.M., Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J. Immunother. 27 (2004), 273–281.
83. Peters, B., Sette, A., Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics, 6, 2005, 132.
84. Postow, M.A., Manuel, M., Wong, P., Yuan, J., Dong, Z., Liu, C., Perez, S., Tanneau, I., Noel, M., Courtier, A., et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J. Immunother. Cancer, 3, 2015, 23.
85. Prehn, R.T., Main, J.M., Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18 (1957), 769–778.
86. Qin, Z., Richter, G., Schüler, T., Ibe, S., Cao, X., Blankenstein, T., B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4 (1998), 627–630.
87. Rasmussen, M., Fenoy, E., Harndahl, M., Kristensen, A.B., Nielsen, I.K., Nielsen, M., Buus, S., Pan-Specific Prediction of Peptide-MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity. J. Immunol. 197 (2016), 1517–1524.
88. Ratan, A., Olson, T.L., Loughran, T.P. Jr., Miller, W., Identification of indels in next-generation sequencing data. BMC Bioinformatics, 16, 2015, 42.
89. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
90. Robbins, P.F., El-Gamil, M., Li, Y.F., Kawakami, Y., Loftus, D., Appella, E., Rosenberg, S.A., A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183 (1996), 1185–1192.
91. Robbins, P.F., Morgan, R.A., Feldman, S.A., Yang, J.C., Sherry, R.M., Dudley, M.E., Wunderlich, J.R., Nahvi, A.V., Helman, L.J., Mackall, C.L., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29 (2011), 917–924.
92. Robbins, P.F., Lu, Y.-C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., Lin, J.C., Teer, J.K., Cliften, P., Tycksen, E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19 (2013), 747–752.
93. Robert, L., Tsoi, J., Wang, X., Emerson, R., Homet, B., Chodon, T., Mok, S., Huang, R.R., Cochran, A.J., Comin-Anduix, B., et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin. Cancer Res. 20 (2014), 2424–2432.
94. Robins, H., Immunosequencing: applications of immune repertoire deep sequencing. Curr. Opin. Immunol. 25 (2013), 646–652.
95. Robinson, J., Waller, M.J., Parham, P., Bodmer, J.G., Marsh, S.G., IMGT/HLA Database-a sequence database for the human major histocompatibility complex. Nucleic Acids Res. 29 (2001), 210–213.
96. Robinson, J., Waller, M.J., Parham, P., de Groot, N., Bontrop, R., Kennedy, L.J., Stoehr, P., Marsh, S.G., IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res. 31 (2003), 311–314.
97. Robinson, J., Halliwell, J.A., McWilliam, H., Lopez, R., Parham, P., Marsh, S.G.E., The IMGT/HLA database. Nucleic Acids Res. 41 (2013), D1222–D1227.
98. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
99. Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
100. Saethang, T., Hirose, O., Kimkong, I., Tran, V.A., Dang, X.T., Nguyen, L.A.T., Le, T.K.T., Kubo, M., Yamada, Y., Satou, K., PAAQD: Predicting immunogenicity of MHC class I binding peptides using amino acid pairwise contact potentials and quantum topological molecular similarity descriptors. J. Immunol. Methods 387 (2013), 293–302.
101. Sahin, U., Türeci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., Pfreundschuh, M., Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92 (1995), 11810–11813.
102. Saul, L., Ilieva, K.M., Bax, H.J., Karagiannis, P., Correa, I., Rodriguez-Hernandez, I., Josephs, D.H., Tosi, I., Egbuniwe, I.U., Lombardi, S., et al. IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Sci. Rep., 6, 2016, 29736.
103. Schultz, K.R., Klarnet, J.P., Gieni, R.S., HayGlass, K.T., Greenberg, P.D., The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science 249 (1990), 921–923.
104. Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512 (2014), 324–327.
105. Scolnick, J.A., Dimon, M., Wang, I.-C., Huelga, S.C., Amorese, D.A., An Efficient Method for Identifying Gene Fusions by Targeted RNA Sequencing from Fresh Frozen and FFPE Samples. PLoS ONE, 10, 2015, e0128916.
106. Şenbabaoğlu, Y., Gejman, R.S., Winer, A.G., Liu, M., Van Allen, E.M., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E., Luna, A., et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol., 17, 2016, 231.
107. Shi, J.-Y., Gao, Q., Wang, Z.-C., Zhou, J., Wang, X.-Y., Min, Z.-H., Shi, Y.-H., Shi, G.-M., Ding, Z.-B., Ke, A.-W., et al. Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma. Clin. Cancer Res. 19 (2013), 5994–6005.
108. Shugay, M., Britanova, O.V., Merzlyak, E.M., Turchaninova, M.A., Mamedov, I.Z., Tuganbaev, T.R., Bolotin, D.A., Staroverov, D.B., Putintseva, E.V., Plevova, K., et al. Towards error-free profiling of immune repertoires. Nat. Methods 11 (2014), 653–655.
109. Shugay, M., Bagaev, D.V., Turchaninova, M.A., Bolotin, D.A., Britanova, O.V., Putintseva, E.V., Pogorelyy, M.V., Nazarov, V.I., Zvyagin, I.V., Kirgizova, V.I., et al. VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires. PLoS Comput. Biol., 11, 2015, e1004503.
110. Shukla, S.A., Rooney, M.S., Rajasagi, M., Tiao, G., Dixon, P.M., Lawrence, M.S., Stevens, J., Lane, W.J., Dellagatta, J.L., Steelman, S., et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33 (2015), 1152–1158.
111. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
112. Srivastava, A., Ghosh, S., Anantharaman, N., Jayaraman, V.K., Hybrid biogeography based simultaneous feature selection and MHC class I peptide binding prediction using support vector machines and random forests. J. Immunol. Methods 387 (2013), 284–292.
113. Szolek, A., Schubert, B., Mohr, C., Sturm, M., Feldhahn, M., Kohlbacher, O., OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 30 (2014), 3310–3316.
114. Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., Chen, S., Klein, A.P., Pardoll, D.M., Topalian, S.L., Chen, L., Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med., 4, 2012, 127ra37.
115. Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H. 2nd, Treacy, D., Trombetta, J.J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352 (2016), 189–196.
116. Tran, E., Turcotte, S., Gros, A., Robbins, P.F., Lu, Y.-C., Dudley, M.E., Wunderlich, J.R., Somerville, R.P., Hogan, K., Hinrichs, C.S., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344 (2014), 641–645.
117. Tran, E., Robbins, P.F., Lu, Y.-C., Prickett, T.D., Gartner, J.J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E.M., et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N. Engl. J. Med. 375 (2016), 2255–2262.
118. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J.M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
119. Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M.H., Goldinger, S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
120. Van den Eynde, B., Hainaut, P., Hérin, M., Knuth, A., Lemoine, C., Weynants, P., van der Bruggen, P., Fauchet, R., Boon, T., Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int. J. Cancer 44 (1989), 634–640.
121. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., Boon, T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991), 1643–1647.
122. Vormehr, M., Schrörs, B., Boegel, S., Löwer, M., Türeci, Ö., Sahin, U., Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. J. Immunol. Res., 2015, 2015, 595363.
123. Wang, P., Sidney, J., Kim, Y., Sette, A., Lund, O., Nielsen, M., Peters, B., Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics, 11, 2010, 568.
124. Warren, R.L., Choe, G., Freeman, D.J., Castellarin, M., Munro, S., Moore, R., Holt, R.A., Derivation of HLA types from shotgun sequence datasets. Genome Med., 4, 2012, 95.
125. Yaari, G., Kleinstein, S.H., Practical guidelines for B-cell receptor repertoire sequencing analysis. Genome Med., 7, 2015, 121.
126. Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P.W., Levine, D.A., et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun., 4, 2013, 2612.
127. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N. Engl. J. Med. 375 (2016), 819–829.
128. Zhang, H., Lund, O., Nielsen, M., The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: application to MHC-peptide binding. Bioinformatics 25 (2009), 1293–1299.
129. Zhang, N., Wu, H.-J., Zhang, W., Wang, J., Wu, H., Zheng, X., Predicting tumor purity from methylation microarray data. Bioinformatics 31 (2015), 3401–3405.
130. Zhang, J., White, N.M., Schmidt, H.K., Fulton, R.S., Tomlinson, C., Warren, W.C., Wilson, R.K., Maher, C.A., INTEGRATE: gene fusion discovery using whole genome and transcriptome data. Genome Res. 26 (2016), 108–118.
131. Zhang, J., Mardis, E.R., Maher, C.A., INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery. Bioinformatics, 2016, btw674.
132. Zhang, X., Sharma, P.K., Peter Goedegebuure, S., Gillanders, W.E., Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine, 2016, 10.1016/j.vaccine.2016.05.073 Published online July 20, 2016.
133. Zheng, X., Zhao, Q., Wu, H.-J., Li, W., Wang, H., Meyer, C.A., Qin, Q.A., Xu, H., Zang, C., Jiang, P., et al. MethylPurify: tumor purity deconvolution and differential methylation detection from single tumor DNA methylomes. Genome Biol., 15, 2014, 419.